Background In Europe, adverse drug reactions and drug interactions are the cause of considerable morbidity and mortality. In over 75s, hospital access due to adverse drug reactions can be as high as 1 in every 3. Aims To assess the quality of the prescribed polytherapies in the territory, in terms of the risk of drug interactions and of prescription appropriateness, in over 75s. Methods Randomly selected patients, over 75s, were analysed among the patients of 3 general practitioners. Their data were analysed with the INTERCheck® software. This software provided the list of drug interactions deriving from the chronic therapies. The program also provided the Beers criteria and the STOPP criteria related to the drugs, highlighting potentially inappropriate drugs. Results A total of 188 patients were included in the study. A total of 216 serious or very serious drug interactions have been identified. A total of 92 patients (48.9%) were at risk of at least one serious or very serious interaction. The cut-off of the correlation between the number of drugs taken and the risk of incurring a serious or very serious interaction was found to be 5 (AUC = 0.833, sensitivity = 87%, p < 0.001). Patients on ≥ 4 drugs were at risk of prescriptive inappropriateness with a sensitivity of 84% (AUC = 0.781, p < 0.0001). Conclusions Focusing on patients with at least 4 drugs in therapy is the right strategy to reduce the risks associated with polypharmacy.
Introduction
Europe's population is getting old. At 1 January 2016, for example in Italy, individuals aged 65 and over represented 22.3% of the total population; those aged 80 and over were 6.8% of the total, while those over 90 years old were 1.2% of the total. The average life span for men has reached 80.6 years, for women 85.1 years [1] . The total population in Europe is projected to increase from 511 million in 2016 to 520 million in 2070. However, the working-age population (people aged between 15 and 64) will decrease significantly from 333 million in 2016 to 292 million in 2070. These projected changes in the population structure reflect assumptions on fertility rates, life expectancy and migration flows. The old-age dependency ratio (people aged 65 and above relative to those aged 15 to 64) in Europe is projected to increase by 21.6 percentage points, from 29.6% in 2016 to 51.2% in 2070 [2] .
"Older patients" in medicine is usually associated with "comorbidity" and "polypharmacy".
Adverse drug reaction (ADR) is defined as "an unpleasant or dangerous reaction, resulting from the use of a pharmaceutical product, which suggests a risk from future administration and determines the need for specific treatment, dosage Electronic supplementary material The online version of this article (https://doi.org/10.1007/s11845-019-02148-8) contains supplementary material, which is available to authorized users. modification or withdrawal of the drug from the market" [3] . The overall number of ADRs is often underestimated as reporting is often on a voluntary basis: 94% of missed reports can be reached [4] . In Europe, adverse drug reactions are the cause of considerable morbidity and mortality. It is estimated that approximately 5% of hospital admissions are due to ADRs, and that they cause around 197,000 deaths a year at the European level. For patients over the age of 75, hospital admission due to an ADR may even be 1 in every 3 [5, 6] .
Drug-drug interactions (DDIs) represent another problem of elderly patients. The comorbidities and the increase in the average age generate polytherapies with high risk of DDI. Drug interactions can compromise the patient's health and cause hospitalisation [7] .
A recent survey conducted in Denmark has shown that general practitioners are often left alone in the management of polypharmacy setup in hospitals [8] . Also, in our study, it emerged that it is unfortunately common that the specialist prescribes following the guidelines without considering the patient's age, the comorbidities and the risks associated with polypharmacy.
The Beers criteria are the most commonly used to support physicians in preventing ADRs in the elderly [9] .
The STOPP criteria (screening tool of older persons) are potentially associated with avoidable adverse drug events capable of causing urgent hospitalisation in the elderly [10] .
The aim of the study was to assess the quality of the prescribed polypharmacy in the territory, in terms of the risk of drug interactions and of prescription appropriateness, in elderly patients over 75 years of age.
Methods
Data were collected from the databases of three general practitioners from the city of Turin, Italy.
The Mario Negri Research Institute in Milan has developed an informatics support system called INTERCheck® to help the clinician in the prevention of DDIs and ADRs. The software provides a list of the potential DDIs associated with the patient's pharmacological therapies, classifying them according to clinical relevance in four categories:
1. Minor: interaction not relevant from the clinical point of view; 2. Moderate: interaction associated with an uncertain or variable event; 3. Major: interaction associated with a serious event; it can be managed (e.g. by adjusting the dose); and 4. Contraindicated or very severe: interaction associated with a serious event; co-administration should be avoided or careful monitoring established.
INTERCheck® has also been validated for clinical practice confirming its effectiveness in reducing severe potential DDIs [11] . The program also provides the Beers criteria and the STOPP criteria related to the drugs present in the chronic therapy of the patient, highlighting the potentially inappropriate drugs and advised against the drugs to be used with caution.
For the purposes of this study, only class C and D interactions were considered. A database was then filled with the patients' personal data, the drugs taken, the interactions emerged, the severity of these interactions and the drugs inappropriately prescribed.
The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki (6th revision, 2008) as reflected in a priori approval by the institution's human research committee.
Statistics
For the analysis of quantitative variables, the Kruskal-Wallis test was used; for the dichotomous qualitative variables, the Fisher test was used. The correlation between quantitative variables was performed with the Pearson test. The ability of the number of drugs in therapy to predict potential DDIs or inappropriate prescriptions was evaluated using receiver operating characteristic (ROC) curve analysis.
A p value of less than 0.05 was considered significant. The statistical analysis was performed with MedCalc Statistical Software version 18.9.1 (MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org; 2018).
Results
A total 188 patients randomly selected among patients with an age greater than or equal to 75 years were selected for the study. Table 1 shows the data regarding the sex and age of the patients enrolled. 53.2% (100) of the patients were male; 46.8% (88) were females. The age ranged from 75 to 96 years and the median was 83.5 years. The largest group of patients was the younger one (75-79). The number of drugs taken ranged from 0 to 17, with an average of 6.5 drugs per patient. In patients older than 84 years, the mean use of drugs per patients was 7.3; in patients younger than 85 years, the mean use of drugs per patients was 5.9 (p = 0.04). There was no significant difference between the female and male population as regards the number of drugs taken (6.5 in both sexes, p = 0.74).
A total of 190 different drugs were prescribed. In supplementary table 1, the most frequently used drugs are reported; the most common one was hydrochlorothiazide followed by acetylsalicylic acid and furosemide.
Considering the pharmacological class of the drugs, diuretics were the most prescribed, followed by β-blockers, proton pump inhibitors and benzodiazepines (supplementary table 2 ).
Overall, pharmacological interactions, classified as serious or very serious, identified by the INTERCheck® software, were 216. A total of 92 patients (48.9% of the total) presented the risk of at least one serious or very serious interaction. Forty-six of these patients were at risk for a class D (very serious) interaction. Figure 1 shows the number of patients presenting an increasing number of serious or very serious risk interactions. The most recurrent cases are those with one or two risk interactions, but there were patients with up to 6 interactions.
An older age was not correlated to the risk of presenting at least one serious or very serious interaction (p = 0.14); the same was applied to sex (p = 0.84).
Instead, a statistically significant correlation emerged between the number of drugs taken and the risk of incurring into a serious or very serious interaction: the cut-off for the predictability was 5 (AUC = 0.833, sensitivity = 86.9%, p < 0.001) (Fig. 2) .
The prescribed drugs involved in serious or very serious interactions were 82 out of a total of 190: in supplementary table 3, the complete list is reported.
The first 4 drugs responsible for class C or D interactions were furosemide, acetylsalicylic acid, escitalopram and sertraline. Specific interactions of these drugs are reported in supplementary table 4, supplementary table 5, supplementary table 6, and supplementary table 7 . Noteworthy, these four drugs alone are responsible for 86 interactions out of a total of 216. The most frequent interaction was between furosemide and digoxin (10 patients, 5.3% of patients). Classifying the drugs into categories, the selective serotonin reuptake inhibitors (SSRIs)/serotonin and norepinephrine reuptake inhibitors (SNRIs) family was the main culprit of potentially dangerous drug interactions: in supplementary table 8, the interactions of this pharmacological class are reported. Twenty-eight percent of all interactions identified were related to this (Fig. 3) .
The list of drugs found to be inappropriate according to the Beers and STOPP criteria is reported in supplementary table 9 .
In particular, the drugs belonging to the benzodiazepine family were found to be inappropriate in 100% of the 56 prescriptions identified in the study patient population. Bromazepam and lorazepam were the two most commonly prescribed molecules. Patient's sex was not associated with the probability of a benzodiazepine prescription (p = 0.79).
Considering proton pump inhibitors (PPIs) (supplementary table 10), 42% of prescriptions were found to be inappropriate. The classes of benzodiazepines, PPI and non-steroidal anti-inflammatory drugs (NSAIDs) alone represented 69% of all inappropriate prescriptions identified (Fig. 4) .
The predictive ability of the number of drugs on the risk of presenting a potentially inappropriate drug in the therapy was then analysed: having at least 4 drugs in therapy predicts this risk with a sensitivity of 84%, AUC = 0.781, and p < 0.0001 ( Fig. 5 ).
Discussion
The study population was balanced for the sex of the participants, as well as for the over-75 age groups included.
It is remarkable that up to until 17 drugs were prescribed to a single patient. A mean of 6.5 drugs per patient was found in our study. This is a significant result because this value is associated with a greater risk of inappropriate prescriptions, DDI and ADR, in literature [12, 13] . Belonging to the older age group (age > 85 years) was associated with the risk of polytherapy. No statistically significant differences were found between the male and female population. It emerged that the most commonly prescribed drugs were hydrochlorothiazide, acetylsalicylic acid and furosemide. Following these three drugs, we found cholecalciferol, bisoprolol and amlodipine, the last two, respectively a β-blocker and a calcium channel blocker, were used in arterial hypertension therapies. It is therefore evident that the drugs used in the treatment of cardiovascular diseases play a preponderant role in composing the polytherapies of our older patients. This data confirms what emerged from a study conducted in Italy in 2009 [14] : even in this case, the most prescribed drugs were those to protect the cardiovascular system. Classifying the drugs according to pharmacological categories, other interesting data emerged. Specifically, a diuretic was found to be prescribed in more than half of the patients, followed by β-blockers, PPIs, benzodiazepines, angiotensin-converting enzyme (ACE) inhibitors and SSRIs. Even PPIs and psychiatric drugs play a significant role in the polytherapies of our elderly, a role that will be analysed later.
It is very significant that almost half of the patients presented the real risk of a DDI classifiable as serious or very serious. It is probably due to the lack of attention at the present time to this problem by health personnel; our patients take a real risk when subjected to complex therapies for equally complex diseases. Our data show that there was no correlation between the risk of presenting a serious or very serious interaction and age; similar assessment can be made for sex. In contrast, other studies found a correlation between the risk of severe interactions and age [14, 15] . This probably derives from the fact that we have included only over-75s patients, while in the 2 studies mentioned, patients over-60-65s have been included. Instead, an important correlation was found between the number of drugs taken and the risk of dangerous DDI. Specifically, the cut-off of 5 drugs allows us to predict with a sensitivity of 87% the risk of presenting at least one potentially serious DDI. This data confirms what is already present in the few studies in the literature in this regard [14, 16] . This data is fundamental because it would make it possible to rationalise the work of the general practitioner, who could in this way focus the evaluation, using INTERCheck® software, in patients with at least 5 drugs in continuous therapy, in order to reduce the workload and to identify potentially dangerous DDI with acceptable sensitivity. The drugs responsible for these DDIs, in order of frequency, were furosemide, followed by acetylsalicylic acid, escitalopram and sertraline: on their own, these four drugs were responsible for 86 interactions out of a total of 216 identified. Grouping the drugs by pharmacological classes showed that 28%, almost a third, of all the identified DDIs were due to a drug belonging to the SSRI/SNRI class. Adding acetylsalicylic acid and furosemide leads to almost half of all identified DDIs. The conclusion is drawn that it would be sufficient for the general practitioner to pay attention to the use of three categories of drugs to avoid almost half of all DDIs of serious or very serious risk class. When a potential risk interaction is identified, the choice can be the deprescription when possible; alternatively, the monitoring (often hematochemical or electrocardiographic).
The study revealed 166 inappropriate prescriptions according to the Beers and STOPP criteria, out of a total of 1220 prescribed drugs (13.6%). The most frequently inappropriate drug was found to be bromazepam, followed by acetylsalicylic acid, lorazepam and pantoprazole.
According to the Beers criteria, "the elderly have an increased sensitivity to benzodiazepines and the metabolism of those with a long duration of action is slower". In general, in the elderly, all benzodiazepines increase the risk of impairment of cognitive abilities, delirium, falls, fractures and road accidents. Those with long half-lives (such as diazepam, flurazepam, flunitrazepam or clonazepam) may be appropriate in the following conditions: seizures, rapid eye movements in sleep disorders, withdrawal from benzodiazepines or ethanol, severe generalised anxiety disorder, periprocedural anaesthesia". The drugs of this class are often prescribed to elderly patients for disorders related to sleep and anxiety by the general practitioner, sometimes by the hospital doctor during hospitalisation. The de-prescription of these drugs is extremely difficult, but it is the right path to take. A systematic review in 2008 showed how the de-prescription of benzodiazepines in the elderly reduces the number of falls and improves cognitive abilities and psychomotor functioning [17] . The solution to this problem should be at the origin: a greater knowledge on the problems connected to sleep and on the clinical and pharmacological way to face them, and a greater attention to the anamnesis and to the first prescription of these molecules, especially in elderly patients.
Regarding PPIs, according to the Beers criteria, "it should be avoided the use for more than 8 weeks except in the following conditions: subjects at high risk (oral therapy with corticosteroids or chronic use of NSAIDs), erosive esophagitis, Barrett's oesophagus, pathological hypersecretion or demonstrated need for maintenance therapy (failure of suspension or ineffectiveness of anti-H2). Rationale for inappropriateness: increases the risk of Clostridium difficile infections, bone loss and fractures". Our results confirmed those of previous studies, like an observational, longitudinal, retrospective and descriptive study in an internal medicine ward in a Portuguese hospital, in which polypharmacy was present in more than 70% of admitted patients and PPIs were the most common inappropriate prescription at discharge (17.2%) [18] . As to the expenses for this overuse/abuse of PPI prescription, it has been shown that PPIs are overprescribed worldwide in both primary and hospital care, so that 25-70% of patients taking these drugs have no appropriate indications and it has been calculated that almost 2 billion pounds are being spent unnecessarily on PPIs each year [19] . It is therefore evident that the prescription of this category of drugs must always pass from a careful evaluation of the risk to benefit ratio, especially in elderly patients.
The study showed a statistically significant correlation between the number of drugs present in the patient's ongoing therapy and the risk that at least one of the prescriptions in therapy was inappropriate. Using the cut-off of 4 drugs, this risk was predicted with a sensitivity of 84% and a specificity of 58%. This data suggests that it could be a good strategy for the general practitioner to focus on patients who have more than 4 drugs in therapy, in order to optimise time and resources. Furthermore, only 3 pharmacological classes accounted for 69% of all the inappropriate prescriptions: this is fundamental. After benzodiazepines, PPIs and NSAIDs were most at risk for inappropriate prescription. In elderly patients, it may be sufficient to focus on these three categories, further facilitating the difficult task of de-prescribing.
Some weaknesses of this study must be emphasised. Since the study was carried out in a relatively small area, its results are not necessarily immediately applicable to other territorial realities, but the consistency of the results found with the data in the literature [14, 15] and the high number of analysed prescriptions (about 1200 prescriptions of 190 different drugs) contribute to giving strength to the study. With regard to the new data that this study brings, if other studies with larger case series have analysed the theme of DDI [14] , very few studies are comparable with our study in analysing prescriptive appropriateness using real data from general practitioners' databases.
In conclusion, the role of the general practitioner appears to be crucial: he is the last prescriber, so he should be the "guardian" of therapies prescribed to patients. This role will have to be confirmed over time, by educating patients to converge on the clinic of their general practitioner following each new prescription suggested by specialists, and by raising awareness among the general practitioners of a careful prescription and de-prescription.
